Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cinhyaluronate sodium
- Development stage
- Phase 3
- Lead developer
- Seikagaku
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
Cinhyaluronate sodium (SI-614) is a modified formulation of hyaluronate developed by Seikagaku for the treatment of dry eye. It is an amphiphilic polymer produced by introducing a hydrophobic group into hyaluronic acid using proprietary technology. As an ophthalmic solution, SI-614 is designed to stabilize the tear film and promote corneal wound healing in patients with dry eye syndrome. Its mechanism involves mucoadhesive and surface tension-reducing properties that help restore normal tear film and corneal structure, potentially offering a new therapeutic option for dry eye based on a novel mechanism not available in existing products[1][2][3].
- Other names
- hyaluronic acid ophthalmicmodified hyaluronate
02
Targets
LYVE1 (Lymphatic vessel endothelial hyaluronic acid receptor 1)RHAMM (Hyaluronan-mediated motility receptor)STAB2 (Stabilin-2)CD44 (CD44 antigen)ICAM1 (Intercellular Adhesion Molecule 1)
Beyond the preview
Go deeper on cinhyaluronate sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cinhyaluronate sodium.